Elucidation of Human Natural Killer Cell Development
人类自然杀伤细胞发育的阐明
基本信息
- 批准号:10587566
- 负责人:
- 金额:$ 57.88万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-05-01 至 2028-04-30
- 项目状态:未结题
- 来源:
- 关键词:Acute Myelocytic LeukemiaAddressAwardBiological AssayBloodBone MarrowCD34 geneCancer EtiologyCancer ModelCancer PatientCell Differentiation processCell LineageCell SeparationCell physiologyCellsCessation of lifeClinicalCoculture TechniquesComplementDataDevelopmentDevelopmental Cell BiologyDevelopmental ProcessEffector CellEndometrialEndometrial CarcinomaFetal DevelopmentFosteringFundingFutureGenetic TranscriptionGoalsGrowthHead and Neck Squamous Cell CarcinomaHematopoietic stem cellsHumanImmuneImmune TargetingImmune systemImmunityImmunologic SurveillanceImmunosuppressionImmunotherapyIn VitroInnate Immune SystemInstitutionInvadedKnowledgeLightLymphoid CellLymphoid TissueMalignant - descriptorMalignant Female Reproductive System NeoplasmMalignant NeoplasmsMeasurementMediatingMethodologyMethodsModelingMolecularMusNatural ImmunityNatural Killer CellsOutcomePathway interactionsPeripheralPhenotypePhysiologicalPhysiological ProcessesPlayPregnancyProcessProductionPropertyPublic HealthPublishingRegulationReportingRoleScientistSeriesShapesSignal TransductionSystemT-LymphocyteTestingTherapeuticTissuesTonsilTumor Cell InvasionTumor ImmunityTumor PromotionTumor-DerivedUnited StatesUterusWomanWorkangiogenesiscancer cellcancer immunotherapyclinically relevantcytotoxicdesigndevelopmental plasticityexperimental studyfibrosarcomahuman tissueimprovedin vivolymph nodesmelanomamouse modelneoplastic cellnovelpermissivenessprecursor cellpreventprognosticprogramsstemtherapeutic targettherapy designtumortumor growthtumorigenic
项目摘要
PROJECT SUMMARY
This proposal focuses on elucidation of the processes regulating human natural killer (NK) cell development
in the healthy state and in the setting of uterine endometrial carcinoma (EC). NK cells are cytotoxic “group 1”
innate lymphoid cells (ILCs) that play myriad roles in immunity and are vital to controlling malignant
transformation. NK cells undergo terminal differentiation and maturation in various tissues throughout the
body, leading to a broad spectrum of NK cell phenotypes and functions. So-called conventional NK cells (cNK)
that arise in secondary lymphoid tissues and predominate in the blood have established roles in
complementing T cell-mediated immune surveillance. In contrast, specialized tissue-resident NK cells (trNK)
and their close cousins, ILC1s, develop in various tissues and are retained there to carry out distinct functions.
In the uterus, trNK cells and ILC1s are physiologically designed to support and promote pregnancy by
promoting placental tissue invasion, immune suppression, and angiogenesis. We hypothesize that in the
setting of EC the normal processes of uterine trNK cell and ILC1 development and function are co-opted by
the tumor cells to promote their growth and invasion. Our goals in this proposal are to gain a comprehensive
understanding of the cellular and molecular components that regulate human NK cell development in healthy
tissues and to determine how these processes are impacted in the setting of EC. Our two specific aims are: 1)
To define NK cell and ILC1 developmental pathways in human tissues; and 2) To determine how NK cell
development and function are shaped by human EC. In particular, in Aim 1 we will test the hypothesis that all
NK cells and ILC1s stem from a common group 1 ILC precursor cell, which we have recently identified in
human lymphoid tissues. We propose a series of experiments to test our hypothesis and to determine the
molecular regulation of the NK cell versus ILC1 developmental axis stemming from the novel precursor cell.
Further, we will elucidate the developmental pathways of NK cells and ILC1s in the healthy human uterus,
testing the hypothesis that uterine NK cells and ILC1s also stem from a similar group 1 ILC precursor cell but
ultimately terminally differentiate through pathways distinct from those in lymphoid tissues. In Aim 2 we will
test the hypothesis that NK cell development from the common group 1 ILC precursor is skewed towards the
production of ILC1s and poorly cytotoxic uterine trNK cells that are permissive if not promoting of tumor
growth. Through our proposed studies we will determine how NK cell development, functional diversity, and
plasticity are shaped by EC. The clinical importance of these studies lies in the fact that EC is the most
common gynecologic malignancy in the United States and is the sixth leading cause of cancer death in
women. Further, we predict that the knowledge gained from our studies will improve our fundamental
understand of human NK cell developmental biology and ultimately the design of future immune-based cancer
therapies for EC and potentially other forms of cancer in which innate immunity is impacted.
项目摘要
这项建议的重点是阐明过程调节人类自然杀伤(NK)细胞的发展
在健康状态下和在子宫内膜癌(EC)的情况下。NK细胞是细胞毒性的“第1组”
先天性淋巴样细胞(ILC)在免疫中起着无数的作用,对控制恶性肿瘤至关重要。
转型NK细胞在整个免疫系统的各种组织中经历终末分化和成熟。
机体,导致广泛的NK细胞表型和功能。传统NK细胞(cNK)
产生于次级淋巴组织并在血液中占主导地位,
补充T细胞介导的免疫监视。相反,特化的组织驻留NK细胞(trNK)
它们的近亲ILC 1在各种组织中发育,并保留在那里执行不同的功能。
在子宫中,trNK细胞和ILC 1在生理上被设计为通过以下方式支持和促进妊娠:
促进胎盘组织侵入、免疫抑制和血管生成。我们假设在
EC的设置,子宫trNK细胞和ILC 1发育和功能的正常过程被
促进肿瘤细胞的生长和侵袭。我们在本提案中的目标是获得全面的
了解调节健康人NK细胞发育的细胞和分子组分
组织,并确定这些过程是如何影响的设置EC。我们的两个具体目标是:1)
确定NK细胞和ILC 1在人体组织中的发育途径;和2)确定NK细胞如何在人体组织中发育,
发育和功能是由人类EC塑造的。具体而言,在目标1中,我们将检验以下假设:
NK细胞和ILC 1来源于一种共同的第1组ILC前体细胞,我们最近在
人类淋巴组织我们提出了一系列的实验来验证我们的假设,并确定
NK细胞相对于ILC 1发育轴的分子调节源自新的前体细胞。
此外,我们将阐明NK细胞和ILC 1在健康人类子宫中的发育途径,
测试子宫NK细胞和ILC 1也来源于类似的第1组ILC前体细胞,
最终通过与淋巴组织不同的途径进行终末分化。在目标2中,
测试NK细胞从常见的第1组ILC前体发育向
产生ILC 1和细胞毒性差的子宫trNK细胞,即使不促进肿瘤,也是允许的
增长通过我们提出的研究,我们将确定NK细胞的发育,功能多样性,
塑性是由EC形成的。这些研究的临床重要性在于EC是最常见的
是美国常见的妇科恶性肿瘤,是美国癌症死亡的第六大原因。
妇女此外,我们预测,从我们的研究中获得的知识将提高我们的基本
了解人类NK细胞发育生物学并最终设计未来基于免疫的癌症
治疗EC和潜在的其他形式的癌症,其中先天免疫受到影响。
项目成果
期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Modeling Human Natural Killer Cell Development in the Era of Innate Lymphoid Cells.
- DOI:10.3389/fimmu.2017.00360
- 发表时间:2017
- 期刊:
- 影响因子:7.3
- 作者:Scoville SD;Freud AG;Caligiuri MA
- 通讯作者:Caligiuri MA
Highly cytotoxic natural killer cells are associated with poor prognosis in patients with cutaneous T-cell lymphoma.
高细胞毒性自然杀伤细胞与皮肤 T 细胞淋巴瘤患者的不良预后相关。
- DOI:10.1182/bloodadvances.2018020388
- 发表时间:2018
- 期刊:
- 影响因子:7.5
- 作者:Mundy-Bosse,Bethany;Denlinger,Nathan;McLaughlin,Eric;Chakravarti,Nitin;Hwang,Susan;Chen,Li;Mao,HsiaoyinCharlene;Kline,David;Youssef,Youssef;Kohnken,Rebecca;Lee,DeanAnthony;Lozanski,Gerard;Freud,AharonG;Porcu,Pierluigi;Willia
- 通讯作者:Willia
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
AHARON G FREUD其他文献
AHARON G FREUD的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('AHARON G FREUD', 18)}}的其他基金
Elucidation of Human Natural Killer Cell Development
人类自然杀伤细胞发育的阐明
- 批准号:
10091309 - 财政年份:2017
- 资助金额:
$ 57.88万 - 项目类别:
Elucidation of Human Natural Killer Cell Development
人类自然杀伤细胞发育的阐明
- 批准号:
9258766 - 财政年份:2017
- 资助金额:
$ 57.88万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 57.88万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 57.88万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 57.88万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 57.88万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 57.88万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 57.88万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 57.88万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 57.88万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 57.88万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 57.88万 - 项目类别:
Research Grant














{{item.name}}会员




